Table 1 Potential targets for antigen-specific breast cancer vaccines and their frequency of mRNA expression, amplification/overexpression1 or mutation2 in breast cancer
From: Challenges to the development of antigen-specific breast cancer vaccines
Target antigen | Expression in breast cancer | Reference |
|---|---|---|
Differentiation antigens | ||
Carcinoembryonic antigen | 50% | [5] |
NY-BR-1 | 80% | [26] |
Cancer-testis antigens | ||
NY-ESO-1 | 24% | [27] |
MAGE-1 | 8% | [27] |
MAGE-3 | 14% | [27] |
BAGE | 2% | [27] |
GAGE | 8% | [27] |
SCP-1 | 31% | [27] |
SSX-1 | 12% | [27] |
SSX-2 | 8% | [27] |
SSX-4 | 14% | [27] |
CT-7 | 30% | [28] |
Amplified/overexpressed antigens | ||
Her2/neu | 40%1 | [29] |
NY-BR-62 | 60%1 | [30] |
NY-BR-85 | 90%1 | [30] |
Tumor protein D52 | 60%1 | [30] |
Mutational antigens | ||
p53 | 17%2 | [31] |